There is considerable interest in the dipeptidyl peptidase IV (DPP-IV) medications for type 2 diabetes treatment because, as a class, dipeptidyl peptidase IV drugs such as Januvia 25 mg pills (sitagliptin) appear to be well tolerated by people on type 2 diabetes treatment and can be used efficiently as monotherapy or as combination therapy together with Metformin (Glucophage, Fortamet, Glumetza drugs) oral diabetic medications. Beneficial effects of Januvia (sitagliptin) and dipeptidyl peptidase IV inhibitors as class on the pancreas beta-cell function raise the possibility that these sitagliptin agents of DPP-IV inhibitors may be able to modify the natural history of type 2 diabetes, given that Januvia used in proper type 2 diabetes treatment plan.
Tag Archives: weight loss
Type 2 sugar diabetes results from a combination of malfunctioning insulin action in the body, and decreased insulin production in the pancreas. Type 2 sugar diabetes symptoms is often associated with high blood cholesterol and triglycerides and high blood pressure. It is also a serious risk of development of heart attack or stroke. In the past, Type 2 sugar diabetes was much less common in children and adolescents, but now it is not true anymore. With youth obesity on the rise, Type 2 sugar diabetes quickly gain ground in that category. Obesity in young people is a major risk fact or that predispose them to Type 2 sugar diabetes.
One of the most frustrating side effects associated with overall blood glucose control improvement in people with diabetes using intensive insulin therapy is weight gain. The addition of Symlin (pramlintide) to intensive insulin therapy for diabetes treatment improves long-term blood glucose control beyond that obtained with insulin therapy alone and significantly decreases weight gain and risk of hypoglycemia events. Pramlintide (Symlin) is an analogue to the native amylin.
Exenatide drug under brand Byetta is a novel GPL-1 (Glucagon-like Peptide-1) incretin mimetic hormone that has been FDA approved for use in poorly managed Type 2 diabetes individuals using sulfonylureas and metformin pills. Glucagon-like Peptide-1 is secreted from enteroendocrine cells located in the ileum and colon in response to a meal. People with Type 2 sugar diabetes and impaired glucose tolerance are GPL-1 (glucagon-like Peptide-1) deficient. When given before a meal, exenatide (Byetta) restores first-phase insulin response in people with Type 2 diabetes. Exenatide reduces postprandial glucagon levels and increases insulin release from the beta cells. Exenatide (Byetta) injections improve gastric emptying and promotes satiety. It is noted that Byetta (exenatide) appears to reduce beta-cell death (apoptosis). Exenatide (Byetta) functions in a glucose-dependent fashion which means that the effects of the exenatide drug are obvious mainly in the presence of hyperglycemia. You can buy exenatide drug Byetta online now from various vendors following selected links to the right.
Obesity, particularly abdominal obesity (accumulation of fat tissue above hips), leads to the production of a number of metabolic products, hormones, and cytokines that favor decreased insulin sensitivity in the liver, muscles, and cardiovascular system. Insulin normally stimulates glucose uptake in muscle and fat, reduces glucose output by liver, and inhibits lipolysis in fat tissue (adipose tissue). In obesity, an increase in free fatty acids from more lipolytically active abdominal adipose cells decreases insulin action in the muscle, fat, and liver. This leads to a decrease in glucose uptake and unchecked glucose output, which contribute to the high blood glucose levels. Moreover, loss of insulin sensitivity leads to further lipolysis and release of free fatty acids in merry-go-round.
Nearly 60,000 bariatric operations are performed every year in the US. Primary goal of bariatric operations is reducing complications associated with clinically severe obesity. Clinically obese people are ripe for onset of Type 2 diabetes. Clinically severe obesity is defined as a body mass index (BMI) greater than 40 kg/m2 or BMI greater than 35 kg/m2 in the presence of a serious comorbid condition such as difficulty breathing, snoring (sleep apnea), sugar diabetes, musculosceletal dysfunction, cardiomyopathy, or high blood pressure (hypertension). In simple words it means that being 100 pounds above ideal body weight or more than 200 percent of ideal body weight is clinical obesity. People with clinically severe obesity have between 1 in 10 and 3 in 10 chance to develop Type 2 diabetes or impaired glucose tolerance. Good news is that a weight loss of 50 percent of excess body weight in people with clinically severe obesity can result in a 30-fold less chance in the development of Type 2 diabetes. Just process this! 3-fold risk reduction if the person get rid of one half of excess weight. While you contemplating this powerful message please pay close attention to the very selective advertisement on this page that I hope will help you further.